Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > On watch
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by TraderBenon Jul 19, 2017 3:35pm
180 Views
Post# 26487258

RE:RE:RE:On watch

RE:RE:RE:On watch
rad10 wrote:
Iattice wrote:
hpwamrs wrote: CXR.TO has been showing support at 1.97 and resistance at 2.88.  From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

https://canada.stoxline.com/q_ca.php?s=cxr.to


Awesome !
 


Gonna get me some..........  



So your senior secured's are now Caa1, eh?  
Dammit.  
Could be worse ..   the unsecured's are Caa3.    

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities